Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
OBJECTIVE: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 - 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review...[Show more]
|Collections||ANU Research Publications|
|Source:||International Journal of Clinical Pharmacology and Therapeutics|
|01_Madden_Lapatinib_plus_capecitabine_in_2018.pdf||443.96 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.